Tesaro Inc.

6 trials Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

0 Recruiting

6 Completed trials

16 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 3 Phase II: 1 Phase I: 2

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Ovarian cancer 2 Endometrial cancer stage III 1 Ovarian cancer stage III 1 Homologous recombination deficiency positive advanced ovarian cancer 1 Endometrial cancer stage IV 1 Ovarian cancer stage IV 1

Top IMPs

NIRAPARIB TOSILATE MONOHYDRATE 3 DOSTARLIMAB 2 BEVACIZUMAB 1 CARBOPLATIN 1 PACLITAXEL 1

All trials

6 total

A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended

2023-506551-23-00 Phase III 13 countries DOSTARLIMAB; NIRAPARIB TOSILATE MONOHYDRATE
Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-507564-39-00 Phase I 1 country
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Phase III 13 countries DOSTARLIMAB; NIRAPARIB TOSILATE MONOHYDRATE
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-506390-35-00 Phase I 6 countries
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T… Ended

2023-505097-16-00 Phase II 1 country BEVACIZUMAB; CARBOPLATIN; NIRAPARIB TOSILATE MONOHYDRATE; PACLITAXEL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar… Ended

2023-508010-42-00 Phase III 12 countries

Showing 1–6 of 6 trials

← All sponsors A–Z